- Home
- NVCR vs ZLAB Comparison
NVCR vs ZLAB Comparison
Compare NVCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- ZLAB
- Stock Information
- Founded
- NVCR 2000
- ZLAB 2013
- Country
- NVCR Jersey
- ZLAB China
- Employees
- NVCR N/A
- ZLAB N/A
- Industry
- NVCR Medical/Dental Instruments
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- ZLAB Health Care
- Exchange
- NVCR Nasdaq
- ZLAB Nasdaq
- Market Cap
- NVCR 1.8B
- ZLAB 1.8B
- IPO Year
- NVCR 2015
- ZLAB 2017
- Fundamental
- Price
- NVCR $17.49
- ZLAB $31.24
- Analyst Decision
- NVCR Buy
- ZLAB Strong Buy
- Analyst Count
- NVCR 5
- ZLAB 4
- Target Price
- NVCR $26.60
- ZLAB $52.50
- AVG Volume (30 Days)
- NVCR 1.3M
- ZLAB 976.3K
- Earning Date
- NVCR 10-30-2024
- ZLAB 11-12-2024
- Dividend Yield
- NVCR N/A
- ZLAB N/A
- EPS Growth
- NVCR N/A
- ZLAB N/A
- EPS
- NVCR N/A
- ZLAB N/A
- Revenue
- NVCR $549,964,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- NVCR $16.23
- ZLAB $48.34
- Revenue Next Year
- NVCR $6.09
- ZLAB $47.12
- P/E Ratio
- NVCR N/A
- ZLAB N/A
- Revenue Growth
- NVCR 8.33
- ZLAB 28.16
- 52 Week Low
- NVCR $10.87
- ZLAB $13.48
- 52 Week High
- NVCR $24.74
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- NVCR 43.24
- ZLAB 70.41
- Support Level
- NVCR $15.61
- ZLAB $31.52
- Resistance Level
- NVCR $17.31
- ZLAB $36.60
- Average True Range (ATR)
- NVCR 1.29
- ZLAB 1.36
- MACD
- NVCR 0.05
- ZLAB 0.34
- Stochastic Oscillator
- NVCR 11.59
- ZLAB 58.60
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.